<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02048072</url>
  </required_header>
  <id_info>
    <org_study_id>ANSG 1.8</org_study_id>
    <nct_id>NCT02048072</nct_id>
  </id_info>
  <brief_title>Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS</brief_title>
  <acronym>ANSG</acronym>
  <official_title>Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jochen Vehoff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to primarily evaluate the impact of Gilenya (Fingolimod) on the
      autonomic nervous system in patients being treated for the first time with Gilenya
      (Fingolimod). Effects on the cardiovascular system will be studied as well. The study is
      conducted to answer the question, if, and if yes, what impact the treatment with Gilenya
      (Fingolimod) has on the autonomic nervous system. To our knowledge little is known about the
      effects of Gilenya (Fingolimod) on the autonomic nervous system. We do know of rare, but
      potentially clinically and therapeutically relevant cardiovascular adverse events of Gilenya
      (Fingolimod). From a scientific point of view the mechanisms by which this is mediated are
      of interest. Maybe a better understanding of these mechanisms might even be of clinical
      relevance (e.g. risk stratification).

      The impact of Gilenya (Fingolimod) on the autonomic nervous system is quantitavely measured,
      using a state-of-the-art technique. Non-invasive blood pressure measurement is performed
      with the Finometer Pro (Finapres Medical Systems, NL) under different paradigms (breathing
      at rest, deep breath, valsalva maneuver, active standing). In addition the sympathetic skin
      reaction is performed. The non-invasive blood pressure measurements are done by continuous,
      plethysmographic blood pressure measurement at the index finger, while the patient is
      performing the tasks mentioned above. By interpreting the blood pressure curve, heart rate
      and blood pressure variability are calculated. The sympathetic skin reaction consists of
      measuring the change of electric conductibility of the skin (palms and soles) after an
      electric stimulus of a peripheral nerve. These parameters allow to assess the functionality
      of four important autonomic functional systems (orthostasis, sympathetic adrenergic,
      sympathetic cholinergic, parasympathetic cholinergic). Normative data has been acquired in
      our lab.

      Our hypothethis is, that there will be a change of heart rate variability at t4,5h compared
      to baseline (t0) for the parameter &quot;RMSSD&quot; under &quot;normal breathing&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>RMSSD</measure>
    <time_frame>t-4,5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>change of heart rate variability at t4,5h compared to baseline (t0) for the parameter &quot;RMSSD&quot; under normal breathing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HRV</measure>
    <time_frame>t=3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>change of heart rate variability at t3mo compared to baseline (t0) and t4,5h for the parameter &quot;RMSSD&quot; under normal breathing, deep breathing and valsalva manouvre</description>
  </secondary_outcome>
  <other_outcome>
    <measure>result of autonomic testing</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>result of the autonomic testing at the three evaluation timepoints (pathologic vs. normal)</description>
  </other_outcome>
  <other_outcome>
    <measure>HR</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>heart rate at the three different evaluation time-points</description>
  </other_outcome>
  <other_outcome>
    <measure>RR</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>arterial blood-pressure at the three different evaluation time-points</description>
  </other_outcome>
  <other_outcome>
    <measure>EDSS</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>expanded disability status scale at the three different evaluation time-points</description>
  </other_outcome>
  <other_outcome>
    <measure>FSS</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>fatigue severity score at the three different evaluation time-points</description>
  </other_outcome>
  <other_outcome>
    <measure>COMPASS 31</measure>
    <time_frame>t=0, t=4,5h, t=3mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>refinded and abbreviated composite autonomic symptom score at the three different evaluation time-points</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Autonomic Nervous System</condition>
  <arm_group>
    <arm_group_label>Gilenya</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilenya</intervention_name>
    <arm_group_label>Gilenya</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for treatment with Gilenya according label

          -  treatment with Gilenya intended

          -  no contraindications for the treatment with Gilanya

          -  all safety-aspects have been fullfilled

          -  age between 18 and 60 years

          -  written consent is given

        Exclusion Criteria:

          -  relapse during the last 30 days befor randomization

          -  steroids within 30 days before randomization

          -  heart rhythm disturbance

          -  new or currently changed dose (last 4 weeks) of bata-blockers, calcium antagonists,
             antidepressants or antiarrhythmics

          -  diabetes mellitus

          -  polyneuropathy

          -  missing consent

          -  pregnancy

          -  lactation period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jochen Vehoff, MD</last_name>
    <phone>+41714941111</phone>
    <email>jochen.vehoff@kssg.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Müller</last_name>
    <phone>+41714941111</phone>
    <email>stefanie.mueller@kssg.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>SG</state>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Vehoff, MD</last_name>
      <phone>+41714941111</phone>
      <email>jochen.vehoff@kssg.ch</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Müller</last_name>
      <phone>+41714941111</phone>
      <email>stefanie.mueller@kssg.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jochen Vehoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Jochen Vehoff</investigator_full_name>
    <investigator_title>Dr. med. Jochen Vehoff</investigator_title>
  </responsible_party>
  <keyword>relapsing remitting</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>fingolimod</keyword>
  <keyword>Gilenya</keyword>
  <keyword>autonomic nervous system</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fingolimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
